DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactCompany

RPG Life Sciences Limited — Slump Sale-XBRL

NSE 1 hr ago·29 Jul 2026, 6:31 pm

RPG Life Sciences

RPG Life Sciences has informed stock exchanges about a slump sale transaction. This corporate action involves transferring specific business assets and liabilities to a newly formed entity. The company has not disclosed the financial value of the deal, but it is a strategic move to streamline operations and focus on core strengths.

For investors, this development signals a potential restructuring of the company's portfolio. It may help RPG Life Sciences reduce debt or shed non-core businesses to improve future profitability. However, the impact on the stock price will depend on the market's perception of the transaction's strategic value and the long-term benefits for the company.

Investors should monitor the company's official filings for more details on the transaction structure and the valuation. Keeping an eye on the company's future financial reports will help assess how this restructuring affects its operational efficiency and growth prospects.